Absci, Oracle and AMD collaborate on AI drug discovery
Cette publication existe aussi en Français
Absci, a biotech company using generative AI for drug discovery, has teamed up with Oracle Cloud Infrastructure (OCI) and AMD to accelerate the development of biologics. The partnership aims to shorten drug design cycles and cut costs by combining Absci’s AI platform with cloud and GPU horsepower.
For eeNews Europe readers, this collaboration highlights how cloud infrastructure and advanced GPUs are pushing AI workloads into new frontiers beyond traditional IT—an important development for semiconductor, cloud, and AI technology ecosystems in Europe and worldwide.
Scaling AI-powered biologics design
Absci has chosen OCI as its backbone for building and scaling AI models, ranging from large-scale molecular-dynamics simulations to full antibody design workflows. With AMD’s latest Instinct MI355X GPUs added to the mix, the company says it is able to further boost the performance and scalability of its Drug Creation Platform.
“Our mission is to push the boundaries of how we design new therapeutics,” said Sean McClain, founder and CEO, Absci. “With OCI and AMD, we are pairing our cutting-edge AI models with best-in-class infrastructure. This collaboration accelerates our ability to bring novel therapeutics to patients while laying the technical foundation for the next generation of AI-powered drug discovery workflows.”
The platform runs on OCI bare-metal instances with 5th Gen AMD EPYC processors and RDMA cluster networking, delivering low-latency GPU access and high throughput. According to Absci, this setup reduces inter-GPU latency to as little as 2.5 µs and enables terabytes-per-second data streaming—capabilities critical for training large models and refining antibody–antigen interactions.
Cloud and silicon players back AI in healthcare
Oracle and AMD executives framed the partnership as a demonstration of how cloud and chip innovation are fueling advances in biotech.
“Absci’s generative AI-driven drug discovery is the kind of breakthrough workflow OCI was built for,” said Dan Spellman, vice president, AI and OCI, Healthcare & Life Sciences, Oracle. “By combining bare-metal GPUs, OCI Compute E6 instances, ultrafast RDMA networking, and high-performance storage, we’re providing the predictable performance and close engineering collaboration Absci needs to push the boundaries of biologics design.”
“Absci is demonstrating how AI can transform the pace of drug discovery, and we’re proud to support that mission,” added Ram Peddibhotla, corporate vice president, Data Center GPU Cloud Business, AMD. “By combining OCI with AMD EPYC CPUs, AMD Instinct GPUs and our open ROCm software platform, this collaboration provides the performance and scalability needed to advance complex biologics design and support more efficient discovery workflows.”
For the fast-moving healthcare AI market, the Absci-Oracle-AMD collaboration underscores how semiconductor and cloud providers are competing to enable compute-heavy workloads, with potential knock-on effects across Europe’s growing biotech and AI sectors.
https://www.oracle.com/
If you enjoyed this article, you will like the following ones: don't miss them by subscribing to :
